Match!

Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold.

Published on May 15, 2020in European Journal of Medicinal Chemistry4.833
· DOI :10.1016/J.EJMECH.2020.112417
Chalada Suebsuwong5
Estimated H-index: 5
(UH: University of Houston),
Bing Dai2
Estimated H-index: 2
(Tufts University)
+ 9 AuthorsAlex N. Bullock40
Estimated H-index: 40
(SGC: Structural Genomics Consortium)
Abstract
Abstract Receptor-interacting protein kinase 2 (RIPK2) is a key mediator of nucleotide-binding oligomerization domain (NOD) cell signaling that has been implicated in various chronic inflammatory conditions. A new class of RIPK2 kinase/NOD signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold was developed. Several co-crystal structures of RIPK2•inhibitor complexes were analyzed to provide insights into inhibitor selectivity versus the structurally related activin receptor-like kinase 2 (ALK2) demonstrating that the inhibitor sits deeper in the hydrophobic binding pocket of RIPK2 perturbing the orientation of the DFG motif. In addition, the structure-activity relationship study revealed that in addition to anchoring to the hinge and DFG via the 2-aminopyridine and 3-phenylsulfonamide, respectively, appropriate occupancy of the region between the gatekeeper and the αC-helix provided by substituents in the 4- and 5-positions of the 3-phenylsulfonamide were necessary to achieve potent NOD cell signaling inhibition. For example, compound 18t (e.g. CSLP37) displayed potent biochemical RIPK2 kinase inhibition (IC50 = 16 ± 5 nM), >20-fold selectivity versus ALK2 and potent NOD cell signaling inhibition (IC50 = 26 ± 4 nM) in the HEKBlue assay. Finally, in vitro ADME and pharmacokinetic characterization of 18t further supports the prospects of the 3,5-diphenyl-2-aminopyridine scaffold for the generation of in vivo pharmacology probes of RIPK2 kinase and NOD cell signaling functions.
  • References (43)
  • Citations (0)
📖 Papers frequently viewed together
6 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References43
Newest
#1Pamela A. Haile (GSK: GlaxoSmithKline)H-Index: 5
#2Linda N. Casillas (GSK: GlaxoSmithKline)H-Index: 8
Last. Robert W. Marquis (GSK: GlaxoSmithKline)H-Index: 24
view all 33 authors...
RIP2 kinase has been identified as a key signal transduction partner in the NOD2 pathway contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. Small-molecule inhibitors of RIP2 kinase or its signaling partners on the NOD2 pathway that are suitable for advancement into the clinic have yet to be described. Herein, we report our discovery and profile of the prodrug clinical compound, inhibitor 3, currently in phase 1 clinical studies. Compound 3 potently b...
Source
#1Matous Hrdinka (Ludwig Institute for Cancer Research)H-Index: 12
#2Lisa Schlicher (Ludwig Institute for Cancer Research)H-Index: 1
Last. Mads Gyrd-Hansen (Ludwig Institute for Cancer Research)H-Index: 26
view all 16 authors...
Abstract RIPK2 mediates inflammatory signaling by the bacteria‐sensing receptors NOD1 and NOD2. Kinase inhibitors targeting RIPK2 are a proposed strategy to ameliorate NOD‐mediated pathologies. Here, we reveal that RIPK2 kinase activity is dispensable for NOD2 inflammatory signaling and show that RIPK2 inhibitors function instead by antagonizing XIAP‐binding and XIAP‐mediated ubiquitination of RIPK2. We map the XIAP binding site on RIPK2 to the loop between β2 and β3 of the N‐lobe of the kinase,...
8 CitationsSource
#1Tatiana Goncharov (Genentech)H-Index: 10
#2Stefanie Hedayati (Genentech)H-Index: 1
Last. Domagoj Vucic (Genentech)H-Index: 33
view all 15 authors...
Summary Inflammatory responses mediated by NOD2 rely on RIP2 kinase and ubiquitin ligase XIAP for the activation of nuclear factor κB (NF-κB), mitogen-activated protein kinases (MAPKs), and cytokine production. Herein, we demonstrate that selective XIAP antagonism blocks NOD2-mediated inflammatory signaling and cytokine production by interfering with XIAP-RIP2 binding, which removes XIAP from its ubiquitination substrate RIP2. We also establish that the kinase activity of RIP2 is dispensable for...
14 CitationsSource
#1Mohamed Salla (U of A: University of Alberta)H-Index: 4
#2Rodrigo Aguayo-Ortiz (U of A: University of Alberta)H-Index: 1
Last. Shairaz Baksh (U of A: University of Alberta)H-Index: 25
view all 22 authors...
Receptor interacting protein kinase 2 (RIP2 or RICK herein referred to as RIPK2) is linked to the pathogen pathway that activates NFkB and autophagic activation. Using molecular modeling (docking) and chemoinformatics analyses we utilized the RIPK2/ponatinib crystal structure and searched in chemical databases for small molecules exerting binding interactions similar to those exerted by ponatinib. The identified RIPK2 inhibitors potently inhibited the proliferation of cancer cells by > 70% as we...
2 CitationsSource
#1Xiaohui HeH-Index: 7
#2Sara Da RosH-Index: 1
Last. Hong LiuH-Index: 9
view all 30 authors...
6 CitationsSource
#1Matous Hrdinka (Ludwig Institute for Cancer Research)H-Index: 12
#2Mads Gyrd-Hansen (Ludwig Institute for Cancer Research)H-Index: 26
The linear ubiquitin chain assembly complex, LUBAC, is the only known mammalian ubiquitin ligase that makes methionine 1 (Met1)-linked polyubiquitin (also referred to as linear ubiquitin). A decade after LUBAC was discovered as a cellular activity of unknown function, there are now many lines of evidence connecting Met1-linked polyubiquitin to NF-κB signaling, cell death, inflammation, immunity, and cancer. We now know that Met1-linked polyubiquitin has potent signaling functions and that its de...
29 CitationsSource
RIP2 kinase is a central component of the innate immune system and enables downstream signaling following activation of the pattern recognition receptors NOD1 and NOD2, leading to the production of inflammatory cytokines. Recently, several inhibitors of RIP2 kinase have been disclosed that have contributed to the fundamental understanding of the role of RIP2 in this pathway. However, because they lack either broad kinase selectivity or strong affinity for RIP2, these tools have only limited util...
26 CitationsSource
#1Peter Canning (SGC: Structural Genomics Consortium)H-Index: 13
#2Qui Ruan (Tufts University)H-Index: 1
Last. Alex N. Bullock (SGC: Structural Genomics Consortium)H-Index: 40
view all 14 authors...
RIPK2 mediates pro-inflammatory signaling from the bacterial sensors NOD1 and NOD2, and is an emerging therapeutic target in autoimmune and inflammatory diseases. We observed that cellular RIPK2 can be potently inhibited by type II inhibitors that displace the kinase activation segment, whereas ATP-competitive type I inhibition was only poorly effective. The most potent RIPK2 inhibitors were the US Food and Drug Administration-approved drugs ponatinib and regorafenib. Their mechanism of action w...
39 CitationsSource
#1Apirat Chaikuad (SGC: Structural Genomics Consortium)H-Index: 26
#2Stefan Knapp (Goethe University Frankfurt)H-Index: 80
Last. Frank von Delft (SGC: Structural Genomics Consortium)H-Index: 26
view all 3 authors...
The quest for an optimal limited set of effective crystallization conditions remains a challenge in macromolecular crystallography, an issue that is complicated by the large number of chemicals which have been deemed to be suitable for promoting crystal growth. The lack of rational approaches towards the selection of successful chemical space and representative combinations has led to significant overlapping conditions, which are currently present in a multitude of commercially available crystal...
20 CitationsSource
#1Ueli Nachbur (University of Melbourne)H-Index: 17
#2Che A. Stafford (University of Melbourne)H-Index: 3
Last. John Silke (University of Melbourne)H-Index: 64
view all 28 authors...
Receptor Interacting Protein Kinase 2 (RIPK2) mediates innate immune signalling in response to intracellular pathogens, but its aberrant activation contributes to autoimmune pathologies. Here Nachbur et al. describe a RIPK2 inhibitor that is effective in a mouse model of multiple sclerosis.
46 CitationsSource
Cited By0
Newest